Pharmaceutical Preparations

Search by Letter:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9

3SBio Inc.

3SBio Inc., a biotechnology company, engages in the research and development, manufacture, and distribution of pharmaceutical products in the People’s Republic of China. Its principal products include EPIAO, an injectable recombinant human erythropoietin to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions; and TPIAO, a ... more

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on drug discovery and clinical development of novel treatments for central nervous system disorders. The company has a portfolio of four product candidates, including pimavanserin, which is in Phase III clinical development as a treatment for Parkinson's disease psychosis. It is also developing AGN-XX/YY, a product candidate in ... more

AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain in the United States. The company develops ARX-01, a Sufentanil NanoTab PCA system, which completed Phase II clinical trial for acute post-operative pain. The Sufentanil NanoTab PCA system consists of sufentanil, a high ... more

Achillion Pharmaceuticals, Inc.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C; and the development of antibacterials for the treatment of resistant bacterial infections. Its drug candidates for the treatment of chronic ... more

Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. Its Aversion Technology is a proprietary platform technology providing abuse deterrent features and benefits to orally administered pharmaceutical drug products containing abusable ... more

AEterna Zentaris, Inc.

Aeterna Zentaris Inc. operates as a late-stage drug development company specialized in oncology and endocrine therapy. Its lead oncology compounds include perifosine, a PI3K/Akt pathway inhibitor that is in Phase 3 registration trial for refractory advanced colorectal cancer and multiple myeloma; and AEZS-108, a doxorubicin-targeted conjugate in Phase II for the treatment of ovarian, ... more

Affymax, Inc.

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. It develops peginesatide (Hematide), which has completed Phase III clinical trial for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production ... more

Akorn, Inc.

Akorn, Inc. engages in the manufacture and marketing of diagnostic and therapeutic pharmaceutical products, hospital drugs, and injectable pharmaceuticals in the United States and internationally. It offers products in various specialty areas, including ophthalmology, antidotes, anti-infectives, pain management, anesthesia, and vaccines. The company’s Ophthalmic segment markets diagnostic ... more

Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products for treating patients with severe and life-threatening disease states in the United States, Europe, Latin America, Japan, and the Asia Pacific. It focuses on developing products for the treatment of diseases in the areas of hematology, ... more

Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals, Inc., a development stage company, focuses on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Its product candidates are based on a proprietary technology, the Staccato system that vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for ... more

Alimera Sciences, Inc.

Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company is developing ILUVIEN, an intravitreal insert in phase-3 clinical trials for the treatment of diabetic macular edema (DME), which is a disease of the ... more

Alkermes plc

Alkermes plc, an integrated biotechnology company, develops medicines that enhance patient outcomes. The company has a diversified portfolio of approximately 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as addiction, schizophrenia, and depression. It manufactures and commercializes VIVITROL for alcohol and ... more

Allos Therapeutics, Inc.

Allos Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of anti-cancer therapeutics. The company provides FOLOTYN (pralatrexate injection), a folate inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma. It also offers FOLOTYN as a single agent and in combination therapy ... more

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics based on RNA interference (RNAi). The company’s lead RNAi therapeutic program includes ALN-RSV01, which is in Phase II clinical trial for the treatment of human respiratory syncytial virus (RSV) infection. Its product pipeline also comprises ALN-VSP, a ... more

AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). Its principal product includes Feraheme (ferumoxytol) injection for intravenous (IV) use, which was approved for marketing in the United States in June 2009 by the U.S. Food and Drug Administration, for use as an IV iron ... more